Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group-Reference-Cited by-同舟云学术

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

Published:2020-01-10 Issue:1 Volume:4 Page:e329
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Daw Stephen,Hasenclever Dirk,Mascarin Maurizio,Fernández-Teijeiro Ana,Balwierz Walentyna,Beishuizen Auke,Burnelli Roberta,Cepelova Michaela,Claviez Alexander,Dieckmann Karin,Landman-Parker Judith,Kluge Regine,Körholz Dieter,Mauz-Körholz Christine,Wallace William Hamish,Leblanc Thierry

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference86 articles.

1. Preliminary results of the multi-center trial GPOH-HD-95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook;Dörffel;Klinische Padiatrie.,2003

2. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study;Mauz-Korholz;J Clin Oncol.,2010

3. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group;Tebbi;Pediatr Blood Cancer.,2012

4. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425;Schwartz;Blood.,2009

5. Dose intensification with ABMT in relapsed and resistant Hodgkin's disease, results of a BNLI randomised trial;Linch;Lancet.,1993

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes;HemaSphere;2024-09

2. Characteristics of relapsed and refractory paediatric Hodgkin lymphoma; a 10-year retrospective study of an LMIC;ecancermedicalscience;2024-07-16

3. Optimizing salvage therapy for Hodgkin lymphoma: progress and future challenges;Expert Review of Hematology;2024-06-27

4. Combining Brentuximab Vedotin With Dexamethasone, High-dose Cytarabine, and Cisplatin as Salvage Treatment in Pediatric Relapsed or Refractory Classic Hodgkin Lymphoma: Two Case Reports;Journal of Pediatric Hematology/Oncology;2024-06-24

5. What is the best salvage therapy for Hodgkin lymphoma?;Current Opinion in Oncology;2024-06-20